Allogeneic stem cell transplantation for chronic myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• Tyrosine-kinase inhibitors (TKIs) have revolutionized chronic myeloid leukemia (CML) treatment.
• Newer generation TKIs offer improved efficacy and tolerability over imatinib.
• Allogeneic stem cell transplantation (SCT) remains a critical option for specific patient groups.

Purpose of the Study:

• To review the current role of allogeneic SCT in managing CML.
• To discuss the indications for SCT in different phases of CML.
• To outline optimal patient selection and transplantation strategies.

Main Methods:

• Review of recent literature on TKI therapy and SCT for CML.
• Analysis of treatment outcomes based on CML phase and prior therapy.
• Synthesis of current guidelines and expert opinions on SCT indications.

Main Results:

• Most chronic phase CML patients achieve optimal response with TKIs, reducing SCT need.
• Accelerated phase CML patients have a lower response rate to TKIs.
• Blast phase CML patients benefit from SCT, often in combination with TKIs.

Conclusions:

• Allogeneic SCT is indicated for a minority of CML patients, primarily those with advanced disease or TKI resistance.
• SCT remains a potentially curative option for blast phase CML.
• Careful patient selection and timely transplantation are crucial for optimal outcomes.